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Summary
Background Encephalitis has many causes, but for most patients the cause is unknown. We aimed to establish the 
cause and identify the clinical diﬀ erences between causes in patients with encephalitis in England. 
Methods Patients of all ages and with symptoms suggestive of encephalitis were actively recruited for 2 years (staged 
start between October, 2005, and November, 2006) from 24 hospitals by clinical staﬀ . Systematic laboratory testing 
included PCR and antibody assays for all commonly recognised causes of infectious encephalitis, investigation for 
less commonly recognised causes in immunocompromised patients, and testing for travel-related causes if indicated. 
We also tested for non-infectious causes for acute encephalitis including autoimmunity. A multidisciplinary expert 
team reviewed clinical presentation and hospital tests and directed further investigations. Patients were followed up 
for 6 months after discharge from hospital.
Findings We identiﬁ ed 203 patients with encephalitis. Median age was 30 years (range 0–87). 86 patients (42%, 95% CI 
35–49) had infectious causes, including 38 (19%, 14–25) herpes simplex virus, ten (5%, 2–9) varicella zoster virus, and ten 
(5%, 2–9) Mycobacterium tuberculosis; 75 (37%, 30–44) had unknown causes. 42 patients (21%, 15–27) had acute immune-
mediated encephalitis. 24 patients (12%, 8–17) died, with higher case fatality for infections from M tuberculosis (three 
patients; 30%, 7–65) and varicella zoster virus (two patients; 20%, 2–56). The 16 patients with antibody-associated 
encephalitis had the worst outcome of all groups—nine (56%, 30–80) either died or had severe disabilities. Patients who 
died were more likely to be immunocompromised than were those who survived (OR=3·44). 
Interpretation Early diagnosis of encephalitis is crucial to ensure that the right treatment is given on time. Extensive 
testing substantially reduced the proportion with unknown cause, but the proportion of cases with unknown cause 
was higher than that for any speciﬁ c identiﬁ ed cause. 
Funding The Policy Research Programme, Department of Health, UK. 
Introduction 
Few high-quality population-based studies of encephalitis 
are done because the syndrome is rare. Worldwide, up to 
85% of cases are of unknown cause, and there is concern 
about new and emerging triggers.1,2 Over the past decade, 
emerging viruses implicated in causing encephalitis 
include the Nipah virus, bat lyssaviruses, and avian 
inﬂ uenza A H5N1.3–5 The case of West Nile virus in North 
America shows the potential for infections to become 
established in new regions if vectors are present, if avian 
hosts are susceptible, and if the environment is 
supportive.6 In the UK, cases of West Nile virus in human 
beings can pass undetected because the infection is not 
endemic and so clinicians might not consider this 
diagnosis.7 Furthermore, the contribution of recently 
described immune-mediated forms of encephalitis, such 
as those associated with voltage-gated potassium channels 
and the N-methyl-D-aspartate (NMDA) receptor 
antibodies,8–11 is unclear.
Encephalitis is associated with high morbidity and 
mortality. An estimated 700 cases of viral encephalitis 
occur yearly in England, of which about 7% are fatal; 
however, both the incidence and case fatality are thought to 
be underestimated.1 If infection is not fatal, individuals 
often have severe physical, cognitive, emotional, be-
havioural, and social diﬃ  culties.12 In the USA, the yearly 
national costs of patients taken to hospital with encephalitis-
associated illness has been estimated at US$630 million.13 
Eﬀ ective interventions exist for some causes of encephalitis. 
Vaccination against mumps, measles, and rubella has 
substantially reduced the number of encephalitis cases 
associated with these diseases.14 Of the viral causes, herpes 
simplex virus and varicella zoster virus have well 
established antiviral treatments, and immunomodulation 
is used to treat patients with acute disseminated 
encephalomyelitis (ADEM) or other immune-mediated 
encephalitides.15 Timely and appropriate treatment is 
crucial for improving acute encephalitis outcome; hence, 
rapid identiﬁ cation of the cause is key.
We present the clinical and aetiological results of a 
prospective study of 203 patients with encephalitis in 
England. We aimed to establish the cause by a systematic 
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diagnostic algorithm and expert review process, ascertain 
clinical diﬀ erences between causes, document the out-
come, and establish a well deﬁ ned cohort for future study.
Methods 
Patients 
We recruited patients for 2 years (staged start between 
October, 2005, and November, 2006) from 24 hospitals in 
three regions of England: London, the southwest, and the 
northwest of England.16 These regions diﬀ er in socio-
economic and urban–rural characteristics, and comprise 
an estimated 11% (5 million people) of the English 
population. Patients were recruited by active promotion 
and through review of cerebrospinal ﬂ uid (CSF) analysis 
requests to pathology departments. We interviewed 
patients or next-of-kin about speciﬁ c exposures, contact 
with any individuals with infection, risk factors, and travel 
or illnesses before symptom onset.
The case deﬁ nition included any person of any age 
admitted to hospital with encephalopathy (altered 
consciousness that persisted for longer than 24 h, 
including lethargy, irritability, or a change in personality 
and behaviour) and with two or more of the following: 
fever or history of fever (≥38ºC) during the presenting 
illness; seizures and/or focal neurological ﬁ ndings (with 
evidence of brain parenchyma involvement); CSF 
pleocytosis (more than four white blood cells per μL); 
electroencephalographic (EEG) ﬁ ndings indicative of 
encephalitis; and abnormal results of neuroimaging (CT 
or MRI) suggestive of encephalitis.
The North and East Devon Multicentre Research Ethics 
Committee granted approval for the study (05/Q2102/22). 
We also obtained local research ethics committee 
approval and Research and Development approval from 
all participating centres. We obtained written informed 
consent from all patients or from their next of kin.
Procedures 
Data recorded included demographic information, 
clinical ﬁ ndings at presentation and discharge, immune 
status (eg, whether an individual was HIV positive or 
Panel 1: First-line testing for cases of encephalitis*
If immunocompetent 
Routine CSF PCR testing
• Herpes simplex virus 1/2
• Varicella zoster virus
• Enterovirus
• Parechovirus
• Adenovirus
• Human herpesvirus-6/7 (<30 years)
• Consider other tests depending on clinical features†
Routine serology
• If increased activity:
 • Mumps or measles
 • Inﬂ uenza A or B
• Human herpesvirus-6/7 (<30 years)
If immunocompromised
CSF PCR
As for immunocompetent, and consider:
• Cytomegalovirus
•  Epstein-Barr virus 
•  Human herpesvirus-6/7
•  JC virus
•  Lymphocytic choriomeningitis virus 
•  HIV
Serology
•  JC virus
•  HIV with consent when appropriate
If travelled abroad 
CSF PCR
As for immunocompetent, and consider:
•  Arboviruses (Japanese encephalitis, dengue, tickborne encephalitis, Nipah virus, 
Murray Valley encephalitis, St Louis encephalitis)
•  Poliomyelitis
•  Rabies
•  West Nile virus
Serology
• Arboviruses (Japanese encephalitis, dengue, tickborne encephalitis, Nipah, Murray 
Valley encephalitis, St Louis encephalitis)
•  Rabies
•  West Nile virus
*Algorithm assumes appropriate investigations were also done when clinically indicated to exclude bacterial, fungal, and 
parasitic infections. †For cervical lymphadenopathy consider cytomegalovirus and Epstein-Barr virus; for respiratory illness 
consider inﬂ uenza A and B; for parotitis and orchitis consider mumps.
Panel 2: Rare causes of encephalitis in England (not 
included in ﬁ rst-line testing)
Viral
Cytomegalovirus, Epstein-Barr virus, ﬂ aviviruses, hepatitis 
viruses, human T-cell lymphotropic virus, lymphocytic 
choriomeningitis virus, parainﬂ uenza virus, parvovirus B19, 
poliovirus, rabies virus, respiratory syncytial virus
Bacterial
Bacillus anthracis, Bartonella henselae, Chlamydophila psittaci, 
Chlamydia trachomatis, Legionella pneumophila, Leptospira spp, 
Listeria monocytogenes, Borrelia burgdorferi, 
Mycoplasma pneumoniae, Mycobacterium tuberculosis, 
Salmonella spp, Streptococcus pneumoniae, 
Streptococcus pyogenes
Rickettsial
Coxiella burnetii, Rickettsia rickettsii
Parasitic
Toxoplasma gondii
Fungal
Histoplasma capsulatum
Virus Reference Department, 
61 Colindale Avenue, London 
NW9 5EQ, UK
julia.granerod@hpa.org.uk
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on immunosuppressive treatment), and results of 
laboratory, EEG, and neuroimaging testing. Samples 
obtained were from the CSF, blood, urine, stool, swabs 
from various sites (eg, throat or rectal), or from post-
mortem examination. We followed up patients at 
6 months after discharge from hospital; outcome was 
scored according to the Glasgow outcome scale.17 Poor 
outcome was deﬁ ned as death or severe disability.
First-line testing (panel 1) included all commonly 
recognised causes of encephalitis, less commonly 
recognised causes in immunocompromised patients, 
and travel-related causes where appropriate. To obtain 
maximum diagnostic sensitivity, we used DNA or RNA 
and antibody assays. A multidisciplinary expert review of 
the clinical presentation, the results of tests, and the 
available samples from patients directed further 
investigation of undiagnosed patients, which included 
assays for second-line infectious causes, including those 
thought to be rare causes of encephalitis in the UK 
(panel 2) and screening of CSF samples for the presence 
of intrathecal production of antibodies.18 Cases of 
Figure 1: Study proﬁ le
*These patients might or might not have fulﬁ lled the inclusion criteria; those 
who were missed either died or were transferred out of hospital before further 
investigation could be done to fully assess eligibility or before consent could be 
obtained. †These patients were ineligible for case deﬁ nition because of lack of 
imaging or EEG results.
268 patients recruited
     32 patients did not meet case deﬁnition
           5 encephalitis†
           5 meningitis
           4 epilepsy
           3 metabolic encephalopathy
           1 acute lymphoblastic leukaemia
           1 acute myocardial infarction
           1 atypical migraine
           1 benign intracranial hypertension possibly 
              secondary to meningitis
           1 dengue fever
           1 HIV seroconversion illness
           1 infantile spasms
           1 myelopathy
           1 newly diagnosed HIV and miliary tuberculosis 
           1 non-Hodgkins lymphoma; HIV; cytomegalvirus 
             reactivation
           1 neutropenic sepsis
           1 non-speciﬁc encephalopathy
           1 progressive multifocal leukoencephalopathy
           1 posterior reversible encephalopathy syndrome
           1 septic encephalopathy
379 patients referred or screened 
      77 alternative diagnoses
      16 refused consent*
      18 missed*
236 patients met case deﬁnition
     33 subsequently excluded
           4 epilepsy
           4 metabolic encephalopathy
           4 primary brain tumours
           4 septic encephalopathy
           3 stroke (1 secondary to septic embolus)
           3 venous sinus thrombosis
           2 posterior reversible encephalopathy syndrome
           2 non-speciﬁc encephalopathy
           1 adenocarcinoma of oesophagus and 
               Wernicke-Korsakoﬀ syndrome
           1 alcoholic encephalopathy
           1 Alper’s disease
           1 Creutzfeldt–Jakob disease
           1 febrile convulsion
           1 hypertensive encephalopathy
           1 subdural haematoma
203 patients with encephalitis 
        included in analysis
Conﬁ rmed Probable Total (%)
Infectious cause (n=86 [42%; 95% CI 35–49%])
Herpes simplex virus 36 2 38* (19)
Mycobacterium tuberculosis 1 9 10 (5)
Varicella zoster virus 9 1 10 (5)
Streptococci 2 2 4† (2)
Enteroviruses 3 ·· 3 (1)
Dual infection 3 ·· 3‡ (1)
Streptococcus pneumoniae 3 ·· 3 (1)
Inﬂ uenza A ·· 2 2 (1)
Neisseria meningitidis 2 ·· 2 (1)
Toxoplasma gondii 2 ·· 2 (1)
Coxiella burnetii ·· 1 1 (0·5)
Epstein-Barr virus ·· 1 1 (0·5)
Enterococcus faecium 1 ·· 1 (0·5)
Human herpesvirus-6 ·· 1 1 (0·5)
HIV 1 ·· 1 (0·5)
JC virus 1 ·· 1 (0·5)
Listeria monocytogenes 1 ·· 1 (0·5)
Pseudomonas spp 1 ·· 1 (0·5)
Sclerosing subacute 
panencephalitis (measles)
1 ·· 1 (0·5)
Immune-mediated cause (n=42 [21%; 95% CI 15–27%])
Acute disseminated 
encephalomyelitis
23 ·· 23 (11)
NMDA receptor antibodies 9 ·· 9 (4)
VGKC antibodies 7 ·· 7 (3)
Secondary to systemic 
vasculitis
1 ·· 1 (0·5)
Multiple sclerosis 1 ·· 1 (0·5)
Paraneoplastic 1 ·· 1 (0·5)
Unknown cause (n=75 [37%; 95% CI 30–44%])
Unknown ·· ·· 75 (37)
Total 203
NMDA=N-methyl-D-aspartate. VGKC=voltage-gated potassium channel. 
*28 herpes simplex virus-1; three herpes simplex virus-2; seven herpes simplex virus 
untyped. †Three group A streptococci; one group B streptococci. ‡Dual ﬁ ndings: 
one Cryptococcus spp and varicella zoster virus, one Mycobacterium tuberculosis and 
Toxoplasma gondii; one Mycobacterium tuberculosis and HIV.
Table 1: Classiﬁ cation and cause of encephalitis 
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unknown cause were tested retrospectively for antibodies 
against voltage-gated potassium channels (n=62) and the 
NMDA receptor (n=48).8,11 All patients older than 50 years 
of age were tested for antibodies to West Nile virus. All 
patients who died and for whom the cause was unknown 
were tested for lyssaviruses. 
We classiﬁ ed cases as conﬁ rmed, probable, possible, or 
non-encephalitis with a deﬁ nite alternative diagnosis, on 
the basis of aetiological case deﬁ nitions.19 We divided 
causes into the following categories: ADEM, antibody-
associated encephalitis (voltage-gated potassium channel 
and NMDA receptor), Mycobacterium tuberculosis, other 
bacterial encephalitis, herpes simplex virus; varicella 
zoster virus, and encephalitis of unknown cause. 
Statistical analyses 
We investigated diﬀ erences in demographic and clinical 
variables and diﬀ erences in laboratory and imaging 
results with Fisher’s exact test. Factors associated with an 
infectious or immune-mediated cause, an unknown 
cause, death, and extended duration of hospital stay were 
studied in univariable and multivariable analyses. All 
variables with p of 0·2 or less in the univariable analyses 
were included in the multivariable regression models. 
Variables were added in a backwards stepwise procedure. 
A p value of less than 0·05 was deemed signiﬁ cant. For 
all outcomes, apart from duration of hospital stay, logistic 
regression was used with associations assessed by odds 
ratios (OR) and their Wald CIs. For duration of hospital 
stay, a log transformation was used to correct bias; normal 
error regression was then used to adjust for any patients 
who died in hospital. 
Role of the funding source 
The sponsors of the study had no role in study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication.
Results 
We recruited 203 patients with encephalitis (ﬁ gure 1), 
with a median age of 30 years (range 0–87); 109 (54%, 
95% CI 47–61) were male. We identiﬁ ed a cause for 128 
cases (63%, 56–70). Speciﬁ c triggers that caused most 
cases were herpes simplex virus, ADEM, antibody-
associated causes (NMDA receptor antibodies and 
voltage-gated potassium channel antibodies), varicella 
zoster virus, and M tuberculosis (table 1). There was strong 
evidence of variation in causes of encephalitis by age 
(p<0·001; ﬁ gure 2) but not by sex (p=0·96).
No patient had indigenously acquired West Nile virus 
or lyssaviruses in the study—one patient who tested 
positive for herpes simplex virus by PCR while on 
holiday from Canada had West Nile virus IgM and IgG 
antibodies. Eight (35%) patients with ADEM had 
serological evidence of recent infection: four from 
Mycoplasma pneumoniae, one from inﬂ uenza A, one 
from inﬂ uenza B, one from group A streptococcus, and 
one from Campylobacter jejuni. One patient with ADEM 
Figure 2: Age distribution of cases by cause
ADEM=acute disseminated encephalomyelitis. ANT=antibody-associated cause. HSV=herpes simplex virus. 
MTB=Mycobacterium tuberculosis. VZV=varicella zoster virus.
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1–4 years (n=20) <1 years (n=15)
Immunocompetent 
patients* (n=172)
Immunocompromised 
patients† (n=31)
Total
Herpes simplex virus 37 (22%, 16–28) 1 (3%, 0·1–17) 38
Acute disseminated encephalomyelitis 23 (14%, 9–19) ·· 23
Antibody-associated encephalitis 15 (9%, 5–14) 1 (3%, 0·1–17) 16
Mycobacterium tuberculosis 9 (5%, 2–10) 1 (3%, 0·1–17) 10
Varicella zoster virus 4 (2%, 0·6–6) 6 (19%, 7–37) 10
Streptococci 4 (2%, 0·6–6) ·· 4
Enterovirus 3 (2%, 0·4–5) ·· 3
Dual ﬁ nding ·· 3 (10%, 2–26) 3
Toxoplasma gondii ·· 2 (6%, 1–21) 2
Epstein-Barr virus ·· 1 (3%, 0·1–17) 1
Human herpesvirus-6 ·· 1 (3%, 0·1–17) 1
HIV ·· 1 (3%, 0·1–17) 1
JC virus ·· 1 (3%, 0·1–17) 1
Listeria monocytogenes ·· 1 (3%, 0·1–17) 1
Pneumococcus ·· 1 (3%, 0·1–17) 1
Other‡ 13 (8%, 4–13) ·· 13
Unknown 64 (37%, 30–45) 11 (35%, 19–55) 75
Data are number (%, 95% CI). The dual ﬁ ndings are the same as for table 2. *Includes cases for whom immune status 
was unknown. †Reasons for immunocompromised status: 18 HIV positive; three on chemotherapy; ten with other 
reasons or exact reason unknown. ‡Other causes include Pseudomonas spp, Coxiella burnetii, Enterococcus faecium, 
meningococcus, pneumococcus, inﬂ uenza A, sclerosing subacute panencephalitis, paraneoplastic encephalitis, 
multiple sclerosis, and encephalitis secondary to systemic vasculitis. 
Table 2: Causes of encephalitis in immunocompetent versus immunocompromised patients 
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also had evidence of intrathecal antibodies against 
M pneumoniae, but of ten patients with encephalitis who 
were tested, none was identiﬁ ed to be positive for 
M pneumoniae by PCR of CSF samples.
Of 172 (85%) immunocompetent individuals with 
encephalitis, 94 (55%, 95% CI 47–62) were male; median 
age was 25 years (range 0–87). Of 31 (15%) immuno-
compromised individuals with encephalitis, 15 (48%; 
30–67) were male; median age was 38 years (range 
7–77). 58% (95% CI 39–75) of the immunocompromised 
patients were HIV positive. The pattern of causes was 
diﬀ erent in these two groups of patients (table 2). 
ADEM and enteroviral encephalitis occurred only in 
immuno competent patients, as did most cases of 
antibody-associated encephalitis. By contrast, varicella 
zoster virus was more common in immunocompromised 
patients than in immuno competent patients. The 
proportion of cases of unknown cause was similar in 
the two groups (table 2). 
Most patients with encephalitis had fever during the 
presenting illness (table 3). More than 50% of patients 
had headache, seizures, lethargy, and personality or 
behavioural changes. Irritability, neck stiﬀ ness, focal 
neurology, and coma were also recorded (table 3). The 
proportion of patients with seizures and irritability 
varied signiﬁ cantly by cause. Most patients with 
All encephalitis*
(n=203)
HSV (n=38) VZV (n=10) Bacterial† (n=13) MTB (n=10) ADEM (n=23) Antibody-associated 
cause‡ (n=16)
Unknown 
(n=75)
p value§
Symptoms or clinical signs
Fever¶ 147 (72, 66–78) 29 (76, 60–89) 5 (50, 19–81) 11 (85, 54–98) 10 (100, 69–100) 18 (78, 56–92) 9 (56, 30–80) 54 (72, 60–82) 0·12
Headache 122 (60, 53–67) 16 (42, 26–59) 7 (70, 35–93) 8 (61, 31–86) 9 (90, 55–100) 17 (74, 51–90) 8 (50, 25–75) 46 (61, 49–72) 0·07
Seizures 105 (52, 45–59) 24 (63, 46–78) 1 (10, 0·2–44) 7 (54, 25–81) 0 (0, 0–31) 7 (30, 13–53) 14 (88, 62–98) 42 (56, 44–67) <0·001
Lethargy 111 (55, 48–62) 16 (42, 26–59) 8 (80, 44–97) 9 (69, 38–91) 3 (30, 7–65) 15 (65, 43–84) 7 (44, 20–70) 45 (60, 48–71) 0·09
Irritability 75 (37, 30–44) 11 (29, 15–46) 4 (40, 12–74) 8 (62, 31–86) 0 (0, 0–31) 10 (43, 23–65) 3 (19, 4–46) 34 (45, 34–57) 0·01
PB change 131 (64, 57–71) 24 (63, 46–78) 7 (70, 35–93) 9 (69, 38–91) 7 (70, 35–93) 10 (43, 23–65) 11 (69, 41–89) 51 (68, 56–78) 0·53
Stiﬀ  neck 46 (23, 17–29) 5 (13, 4–28) 3 (30, 7–65) 2 (15, 2–45) 3 (30, 7–65) 10 (43, 23–65) 1 (6, 0·1–30) 17 (23, 14–34) 0·08
Focal neurology 73 (36, 29–43) 16 (42, 26–59) 6 (60, 26–88) 2 (15, 2–45) 2 (20, 2–56) 10 (43, 23–65) 8 (50, 25–75) 21 (28, 18–40) 0·10
Coma|| 37 (18, 13–24) 9 (24, 11–40) 2 (20, 2–56) 0 (0, 0–25) 1 (10, 0·2–44) 1 (4, 0·1–22) 2 (12, 1–38) 19 (25, 16–37) 0·20
Neurological signs** 61 (30, 24–37) 9 (24, 11–40) 4 (40, 12–74) 2 (15, 2–45) 2 (20, 2–56) 8 (35, 16–57) 4 (25, 7–52) 24 (32, 22–44) 0·77
Gastrointestinal 
symptoms**††
98 (48, 41–55) 13 (34, 20–51) 3 (30, 7–65) 9 (69, 38–91) 4 (40, 12–74) 15 (65, 43–84) 4 (25, 7–52) 44 (59, 47–70) 0·01
Respiratory 
symptoms**††
41 (20, 15–26) 5 (13, 4–28) 1 (10, 0·2–44) 1 (8, 0·2–36) 1 (10, 0·2–44) 14 (61, 38–80) 1 (6, 0·1–30) 15 (20, 12–31) <0·001
Rash** 23 (11, 7–16) 2 (5, 0·6–18) 5 (50, 19–81) 2 (15, 2–45) 1 (10, 0·2–44) 0 (0, 0–15) 1 (6, 0·1–30) 10 (13, 7–23) 0·01
Photophobia** 16 (8, 5–12) 3 (8, 2–21) 0 (0, 0–31) 1 (8, 0·2–36) 0 (0, 0–31) 1 (4, 0·1–22) 1 (6, 0·1–30) 10 (13, 7–23) 0·84
Urinary 
symptoms**††
21 (10, 6–15) 1 (3, 0·1–14) 0 (0, 0–31) 0 (0, 0–25) 6 (60, 26–88) 7 (30, 13–53) 0 (0, 0–21) 5 (7, 2–15) <0·001
CSF results
CSF pleocytosis‡‡ 159/198 
(80, 74–86)
33/37 
(89, 74–97)
9 
(90, 55–100)
12 
(92, 64–100)
10 
(100, 69–100)
17/20 
(85, 62–97)
11 
(69, 41–89)
53/74 
(72, 60–81)
0·1
CSF protein§§ 120/191 
(63, 55–70)
24/34 
(71, 52–85)
7 
(70, 35–93)
7/11 
(64, 31–89)
10 
(100, 69–100)
11/20 
(55, 31–77)
7 
(44, 20–70)
41/72 
(57, 45–69)
0·06
CSF:blood glucose 
ratio¶¶
45/129 
(35, 27–44)
5/18 
(28, 10–53)
2/6 
(33, 4–78)
5/8 (63, 24–91) 8/9 
(89, 52–100)
4/13 
(31, 9–61)
4/15 
(27, 8–55)
13/48 
(27, 15–42)
0·01
Neuroimaging or neurophysiology
CT 51/170 
(30, 23–37)
18/32 
(56, 38–74)
3/7 
(43, 10–82)
2/12 
(17, 2–48)
3 
(30, 7–65)
6/16 (38, 15–65) 2/12 
(17, 2–48)
13/67 
(19, 11–31)
0·01
MRI 102/169 
(60, 53–68)
25/28
(89, 71–98)
3/7 
(43, 10–82)
1/9 
(11, 0·3–48)
3/7 
(43, 10–81)
22/22 
(100, 85–100)
4 
(25, 7–52)
34/65 
(52, 39–65)
<0·001
EEG 100/120 
(83, 75–89)
22/27 
(81, 62–94)
2/4 
(50, 7–93)
4/6 
(67, 22–96)
3/3 
(100, 29–100)
10/10 
(100, 69–100)
13 
(81, 54–96)
38/44
(86, 73–95)
0·26
Data are number (%, 95% CI). ADEM=acute disseminated encephalomyelitis. CSF=cerebrospinal ﬂ uid. HSV=herpes simplex virus. MTB=Mycobacterium tuberculosis. PB=personality and/or behavioural. 
VZV=varicella zoster virus. *All encephalitis includes those from other causes (not shown). †Includes Neisseria meningitidis, Streptococcus pneumoniae, Listeria spp, Enterococcus faecium, Pseudomonas spp, and 
group A or B streptococci. ‡Includes voltage-gated potassium channel antibodies and anti-NMDA receptor antibodies. §Fisher’s exact test, comparing aetiological categories (except all encephalitis). ¶Fever at 
time of admission. ||Coma was deﬁ ned as a Glasgow outcome scale admission score of ≤8. **These symptoms were not actively sought in every case but documented if they were included in the “other” box of 
our questionnaire; thus, this represents the minimum proportion of patients with these symptoms or clinical signs because we only know if they were present or not known. ††Gastrointestinal symptoms were 
predominantly vomiting and diarrhoea; respiratory symptoms included cough, sore throat, sinusitis, runny nose, upper respiratory tract infection, and dyspnoea; and urinary symptoms included urinary tract 
infection, dysuria, urinary retention, and incontinence. ‡‡Pleocytosis was recorded if white-blood cell counts were >14 μL in neonates, >10 μL in infants (aged 1 month to 12 months), and >4 μL in all others. 
§§Abnormal protein deﬁ ned as greater than 0·5 g/L. ¶¶Abnormal ratio deﬁ ned as CSF:blood glucose less than 0·50. 
Table 3: Summary of clinical ﬁ ndings for patients with encephalitis, by cause   
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antibody-associated encephalitis had seizures, as did 
more than half of those with herpes simplex virus and 
unknown cause (table 3). By contrast, few patients with 
ADEM, varicella zoster virus, and M tuberculosis had 
seizures. The presence of respiratory symptoms, urinary 
symptoms, rash, and gastrointestinal symptoms also 
varied signiﬁ cantly by cause. Respiratory symptoms 
were more common in patients with ADEM than in any 
other group. Higher proportions of patients with ADEM 
or M tuberculosis had urinary symptoms, which were 
rare in any other group. Rash was most common in 
patients with varicella zoster virus. Gastrointestinal 
symptoms (predominantly vomiting) were present in 
nearly half of all patients with encephalitis and were 
most common in patients with bacterial or unknown 
causes and ADEM (table 3). Although evidence of 
aetiological variation was weaker for other clinical 
symptoms or signs, there were notable diﬀ erences. 
Although fever was present in most patients with 
encephalitis, ﬁ ve with varicella zoster virus and seven 
with antibody-associated causes were afebrile. Focal 
neurological symptoms were most common in cases of 
varicella zoster virus (table 3).
The presence of pleocytosis and abnormal protein in 
the CSF did not vary signiﬁ cantly between patients with 
diﬀ erent causes of encephalitis; however, the proportion 
of patients with an abnormal ratio of CSF to blood 
glucose did vary signiﬁ cantly (table 3). About 30% of 
patients with viral or immune-mediated encephalitis and 
an unknown cause had an abnormal ratio (table 3). Many 
patients with bacterial causes of encephalitis had an 
abnormal glucose ratio (table 3). Bacterial causes were 
also associated with increased white-cell counts (table 4).
170 patients (84%) had CT, 169 (83%) MRI, and 120 
(59%) EEG (table 3). There was strong evidence of 
variation by cause in patients with abnormal CT and 
abnormal MRI ﬁ ndings, but not with an abnormal EEG 
ﬁ nding (table 3). Patients with herpes simplex virus 
were most likely to have abnormal CT, whereas patients 
with antibody-associated and bacterial encephalitis were 
least likely to have abnormal CT. CT scans were 
abnormal in nearly a ﬁ fth of patients with unknown 
cause. MRI was most likely to be abnormal in patients 
with ADEM and herpes simplex virus and least likely to 
be abnormal in patients with antibody-associated 
encephalitis and patients with bacterial causes. MRI 
Median white blood-
cell count per μL in CSF 
(IQR)
Proportion of white 
blood cells that are 
lymphocytes (%; IQR)
Median protein 
concentration in CSF 
(g/L; IQR)
Median glucose 
concentration in CSF 
(mmol/L; IQR)
All encephalitis*(n=203) 47 (16–130) 95 (80–100) 0·6 (0·35–1·2) 3·3 (2·7–3·9)
Herpes simplex virus (n=38) 43 (14–140) 92 (77·5–100) 0·6 (0·4–1) 3·3 (2·7–3·7)
Varicella zoster virus (n=10) 54 (23–146) 95 (89–99) 1·1 (0·6–1·8) 4·3 (3–5·5)
Bacterial cause† (n=13) 126 (30–575) 73 (50·5–95) 0·8 (0·4–3·7) 2·6 (1·8–3·8)
Mycobacterium tuberculosis (n=10) 84 (36–216) 99 (88–100) 1·4 (0·8–2·1) 2 (1·6–2·7)
Acute disseminated encephalomyelitis (n=23) 43 (22–115) 100 (95–100) 0·5 (0·4–0·8) 2·9 (2·6–3·4)
Antibody-associated encephalomyelitis ‡ (n=16) 22 (6·5–60) 98 (93–100) 0·3 (0·2–0·5) 3·7 (3·3–4·3)
Unknown (n=75) 47 (16–118·5) 95 (70–100) 0·5 (0·3–1·1) 3·4 (2·9–4)
CSF=cerebrospinal ﬂ uid.*All encephalitis includes those from other causes (not shown as separate category). †Includes Neisseria meningitidis, Streptococcus pneumoniae, 
Listeria spp, Enterococcus faecium, Pseudomonas spp, and group A/B streptococci. ‡Includes voltage-gated potassium channel antibodies and anti-NMDA receptor antibodies. 
Table 4: Summary of CSF investigations for patients with encephalitis 
ENC* (n=198) HSV (n=38) VZV (n=10) Bacterial† (n=13) MTB (n=10) ADEM (n=23) ANT‡ (n=16) Unknown (n=70) p value¶
Glasgow outcome scale
Fatalities 24 (12; 8–17) 4 (11; 3–25) 2 (20; 2–56) 1 (8; 0·2 –36) 3 (30; 7–65) 1 (4; 0·1 –22) 3 (19; 4–46) 6 (9; 3–18) 0·26
Vegetative state 0 (0; 0–2) 0 (0; 0–9) 0 (0; 0–31) 0 (0; 0–25) 0 (0; 0–31) 0 (0; 0–15) 0 (0; 0–21) 0 (0; 0–5) ··
Severe disability 45 (23; 17–29) 11 (29; 15–46) 2 (20; 2–56) 2 (15; 2–45) 2 (20; 2–56) 3 (13; 3–34) 6 (38; 15–65) 16 (23; 14–34) 0·66
Moderate disability 43 (22; 16–28) 8 (21; 9–37) 2 (20; 2–56) 4 (31; 9–61) 2 (20; 2–56) 3 (13; 3–34) 6 (38; 15–65) 11 (16; 8–26) 0·46
Good recovery 86 (43; 36–51) 15 (39; 24–57) 4 (40; 12–74) 6 (46; 19–75) 3 (30; 7–65) 16 (70; 47–87) 1 (6; 0·1 –30) 37 (53; 40–65) 0·02
Admission details
Median length (range) of 
stay (days)§
28 (2–521) (n=200) 30 (5–521) 30 (10–248) 22 (8–128) 87 (26–201) 17 (6–137) 89 (14–407) 24 (2–225) (n=72)
Data are n (%, 95% CI). According to the Glasgow outcome scale, good recovery is deﬁ ned as resumption of normal activities even though there might be minor neurological or psychological deﬁ cits. ADEM=acute 
disseminated encephalomyelitis. ANT=antibody-associated. ENC=all encephalitis. HSV=herpes simplex virus. MTB=Mycobacterium tuberculosis. VZV=varicella zoster virus. *All encephalitis includes “other causes” 
group not displayed as separate aetiological category. †Includes Neisseria meningitidis, Streptococcus pneumoniae, Listeria spp, Enterococcus faecium, Pseudomonas spp, and group A/B streptococci. ‡Includes voltage-
gated potassium channel antibodies and anti-NMDA receptor antibodies. §Only including cases where admission history clear. ¶Fisher’s exact test comparing aetiological categories (except all encephalitis).
Table 5: Outcome of 198 patients with encephalitis 
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scans were abnormal in about a third of patients with 
unknown cause. 
Outcome data were available for 198 patients (97%); ﬁ ve 
patients were lost to follow-up. 24 patients died; death was 
most common in patients with M tuberculosis, varicella 
zoster virus, and antibody-associated encephalitis (table 5). 
The worst outcome was seen in patients with antibody-
associated encephalitis or M tuberculosis (table 5). The 
median length of hospital stay for these two groups was 
nearly three times longer than that for all cases. The 
outcome was poor in 15 (39%, 24–57) patients with herpes 
simplex virus and in 22 (31, 21–44) cases of unknown 
cause. The proportion of patients with poor outcome was 
higher in those with antibody-associated encephalitis than 
in those with bacterial encephalitis (p=0·05), ADEM 
(p=0·01), or encephalitis of unknown cause (p=0·03). 
Patients with ADEM had the best outcome (p=0·02), with 
more than two-thirds making a good recovery (table 5). 158 
patients (78%, 71–83) of all those with encephalitis received 
aciclovir; the median time from hospital admission to 
initiation of aciclovir was 1 day (range 0–93).
Patients with infectious causes were less likely to have 
respiratory symptoms but were more likely to have 
abnormal CSF protein concentrations than were patients 
with immune-mediated causes (table 3). Patients with 
encephalitis of unknown cause were more likely to have 
photophobia but were less likely to have an abnormal 
CSF white cell count and focal neurological symptoms 
than were all cases of known cause (table 3 and table 6).
In logistic regression analyses for which death was an 
outcome, patients who died were more likely to be 
immunocompromised than were patients who did not die 
(table 6). Similar ﬁ ndings were reported when the length 
of hospital stay was used as the outcome measure after 
adjustment for potential confounders (data not shown).
Discussion 
Less than half of patients presenting with encephalitis 
had a proven infectious cause in this study. Herpes 
simplex virus was the most common infectious cause, 
followed by varicella zoster virus and M tuberculosis. 
Thus, more than a quarter of patients were potentially 
treatable with aciclovir. This result conﬁ rms previous 
reports of the important role of herpes simplex virus as 
a cause for sporadic acute infectious encephalitis, and 
of the increasing recognition of the role of varicella 
zoster virus, particularly in immunocompromised 
individuals.20,21 
The identiﬁ cation of M tuberculosis is clinically 
important because not only do these patients need 
speciﬁ c treatment, but this cause is also associated with 
high mortality and poor outcome. Although most of 
these patients had fever, headache, and personality or 
behavioural changes, only a third had neck stiﬀ ness. 
Most cases of M tuberculosis in this study were classiﬁ ed 
as probable rather than conﬁ rmed cases, indicating the 
diﬃ  culty of detection of M tuberculosis in the CNS.19,22 
1% of cases were caused by enteroviruses, similar to the 
results of a study in France,23 but lower than that reported 
in a study in California.24 Enterovirus encephalitis is more 
prevalent in children than in adults and is often mild, 
although disease associated with enterovirus 71 has high 
morbidity.25 Diﬀ erences in the proportion of children 
recruited or in the severity of illness might explain the 
diﬀ erence between studies; in the California cohort, 45% 
were children, whereas 10% were children in the French 
study and 34% were children in this study. Fewer 
children than expected were recruited, perhaps because 
children are less likely than adults to have a lumbar 
puncture in the UK, one of our main methods of case 
ascertainment.26 In view of the importance of accurate 
diagnosis to establish appropriate treatment, lumbar 
punctures in children with encephalitis are indicated.
About a ﬁ fth of patients had immune-mediated 
encephalitis—mostly ADEM. Most studies of encephalitis 
have not distinguished ADEM from other acute 
encephalitides. However, identiﬁ cation of such patients 
is important as treatment strategies involve immuno-
modulation. Patients with ADEM seem to meet the same 
case deﬁ nition and present in similar ways to acute 
Infectious versus immune-mediated Known versus unknown Outcome–death
Odds ratio (95% CI) p value Odds ratio (95% CI) p value Odds ratio (95% CI) p value
Immunocompromised ·· ·· ·· ·· 3·44 (1·28–9·27) 0·01
Focal neurological symptoms ·· ·· 0·51 (0·26–0·98) 0·003 ·· ··
Respiratory symptoms 0·19 (0·07–0·53) 0·002 ·· ·· ·· ··
Photophobia ·· ·· 3·86 (1·3–11·49) 0·01 ·· ··
CSF pleocytosis ·· ·· 0·38 (0·18–0·8) 0·01 ·· ··
Abnormal CSF protein 3·49 (1·46–8·32) 0·005 ·· ·· ·· ··
CSF=cerebrospinal ﬂ uid. Age, sex, cause, fever, headache, seizures, lethargy, irritability, personality or behavioural change, stiﬀ  neck, coma, neurological signs (non-focal), 
gastrointestinal symptoms, rash, urinary symptoms, abnormal CSF:blood glucose ratio, abnormal CT, abnormal MRI, and abnormal EEG were additional variables included in 
the models and had no signiﬁ cant association. To minimise loss of data and increase power, abnormal CSF:blood glucose ratio and coma were excluded from the infectious 
versus immune-mediated model; abnormal CSF:blood glucose ratio, coma, abnormal CT, and abnormal MRI were excluded from the known versus unknown model; 
abnormal CSF:blood glucose ratio and abnormal CT were excluded from the outcome model. 
Table 6: Summary of ﬁ nal regression models, by variable
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infectious encephalitis. Although most patients with 
ADEM were children, 20% were aged 20 years or older. In 
35% of patients with ADEM, there was serological 
evidence of an infection, commonly M pneumoniae, which 
is increasingly but controversially linked to ADEM.27 61% 
of patients with ADEM had a preceding respiratory 
illness, consistent with M pneumoniae and other 
respiratory pathogens as precipitants.
We found 16 patients with antibody-associated 
encephalitis in otherwise unexplained cases. The results 
of this study highlights the epidemiological importance 
of these antibodies in a population-based cohort of 
patients; previous studies report case series,9,10,28 although 
ten patients with NMDA receptor antibodies possibly 
associated with mycoplasma infections were identiﬁ ed in 
the California Encephalitis Project.28 Our detection of 
antibodies to both NMDA receptors and voltage-gated 
potassium channels in patients with suspected acute 
encephalitis—especially when associated with features of 
limbic encephalitis, prominent seizures, normal CT 
scans, absence of fever, and only mild CSF pleocytosis—
suggests that serological testing is important so that 
immunomodulation is instituted promptly, as this 
approach seems to be eﬀ ective if given early.8 Further-
more, underlying tumours should be sought because 
these encephalitides can be paraneoplastic. Although 
obtained prospectively, most cases of antibody-associated 
encephalitis in our study were diagnosed at the 
conclusion of the study when the samples received 
further testing. Therefore, the delay to diagnosis could 
account for the poor outcome observed in this group. We 
are now testing all patients, including those for whom a 
viral cause was identiﬁ ed, to study whether antibodies 
could also have a role in infections. We did not detect 
any evidence of indigenous human West Nile virus 
infection in patients aged older than 50 years—the age-
group most at risk for neuroinvasive disease.6 Although 
no indigenous cases of West Nile virus have been 
detected in the UK, this virus remains a concern because 
of climate change and vectors being present in the UK.
Prompt distinction between causes of acute encephalitis 
is essential to direct appropriate management. We 
conﬁ rmed the well described clinical ﬁ ndings for viral, 
bacterial, and mycobacterial causes. However, no single 
presenting symptom, sign, or CSF measurement could 
alone or in combination accurately separate one group 
from another. At presentation, only a few patients with 
proven infectious causes had neither fever nor CSF 
pleocytosis (24% and 11%, respectively, for herpes simplex 
virus); encephalitides cannot be excluded because 
patients are afebrile with normal CSF. 
Seizures, especially in the absence of fever, should alert 
clinicians to antibody-associated encephalitis because this 
symptom commonly occurs in NMDA receptor and 
voltage-gated potassium channel encephalitides.8,9 Gastro-
intestinal symptoms were common in patients with 
bacterial encephalitides and might be associated with 
systemic infection, and in the ADEM group, these 
symptoms could be a manifestation of the precipitant 
infection. Similarly, the high rates of urinary symptoms 
noted in patients with ADEM or M tuberculosis infection 
might be associated with the tendency of these diseases to 
involve the spinal cord. The high rate of EEG abnormalities 
across the cohort is indicative of encephalopathy, a key 
requirement for recruitment into this study; but EEG did 
not help with distinction between causes. Our data 
provide further evidence that MRI is more sensitive than 
CT in revealing parenchymal change in encephalitis. 
However, we did not investigate the patterns or timings 
of appearance of MRI abnormalities within the diﬀ erent 
groups. In keeping with most results from encephalitis 
studies, we detected slightly more male than female 
patients—whether men and boys are more susceptible 
to encephalitis, or indeed whether they have greater 
exposure to causative agents, needs to be established. 
The number of deaths (12%) in this study was higher 
than that previously described in England for cases of 
viral encephalitis (7%).1 This rate was also higher than 
the 2% and 7% rates described in North America,13,20 but 
was similar to those reported in a recent French study 
(10%).23 We reported deaths in the community because 
patients were followed up 6 months after discharge from 
hospital. Although the study might have been biased 
towards more severe cases, the 10% mortality in those 
with encephalitis from herpes simplex virus was 
substantially lower than that reported in the aciclovir 
treatment trials (19–28%).29,30 Surprisingly, the outcome 
of cases of unknown cause was similar to those with 
herpes simplex virus—results from earlier studies have 
associated failure to identify a cause with a better 
outcome.13,31 Logistic regression analyses indicated that 
patients who died were more likely to be immuno-
compromised than were those who survived.23 In 
addition to the substantial long-term morbidity present 
in many patients, their median hospital stay in this study 
was 28 days (IQR 15–62), indicating an important 
economic burden.13 
Systematic use of molecular diagnostics coupled with 
investigation for non-infectious causes might explain the 
low proportion of cases of unknown cause (37%) 
compared with the 60% previously described1—a lower 
proportion than that reported in most other studies.2 
Despite this ﬁ nding, the proportion of cases with 
unknown cause was higher than that for any speciﬁ c 
identiﬁ ed cause. Explanations include the failure to 
identify non-encephalitic syndromic mimics, inadequate 
case investigation, and the presence of novel infectious 
or non-infectious encephalitis causes. 
Although the three geographical areas encompassed 
both rural and urban communities, as well as areas of 
diﬀ erent socioeconomic means, the age, sex, and ethnic 
origin of this cohort did not diﬀ er from the general 
population in England. Bias towards ascertainment of 
severe encephalitis cases might be present because more 
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than 60% of patients were transferred from a ﬁ rst 
hospital of admission to more specialised units. Both 
mild and severe cases in study hospitals and severe cases 
transferred from other hospitals were studied; however, 
non-referred mild cases might not have been ascertained. 
Bias towards mild cases might also have occurred because 
of challenges in recruiting patients who died soon after 
admission, although we were only notiﬁ ed of few such 
cases. Of all patients initially screened, about a third had 
proven non-encephalitis illnesses, which presented as 
mimics of encephalitis, as described in other studies.32
Timing of sample acquisition during CNS infections 
aﬀ ects test positivity and this factor might have 
contributed to failure to identify organisms.33 The largest 
proportion of unknown causes was seen in children 
compared with older adults, as reported in other studies.13 
Cases of ADEM were unlikely to be among the group 
with unknown cause because most had ADEM excluded 
after MRI head scans. Although undescribed microbes 
or novel immune-mediated causes might contribute to 
cases classiﬁ ed as unknown, non-encephalitic causes 
should also be considered. The poor outcome we report 
in those for whom a cause could not be identiﬁ ed 
emphasises the importance of further research to deﬁ ne 
causality in these patients.
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